Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New score could spare epilepsy patients from invasive brain probes

NCT ID NCT06138808

Knowledge-focused Sponsor: Duke University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a simple scoring system, called the 5-SENSE score, can accurately predict where seizures begin in the brain. Researchers will test this in 400 people with hard-to-treat epilepsy who are already scheduled for an invasive brain test called SEEG. If the score works well, it may help some patients avoid this risky procedure in the future.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients will be prospectively recruited at 20-25 epilepsy centers from North America, Europe, Australia and Asia.

Ages

15 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients aged 15 years or older in whom no direct surgical approach can be offered and who are discussed in the multidisciplinary team discussion * availability of complete non-invasive presurgical work-up (including high-resolution MRI according to the in-center epilepsy protocol, video-telemetry with the recording of a minimum of one habitual clinic and EEG seizure, available as original files for review) Exclusion Criteria: * no telemetry/scalp EEG in center * no protocol MRI in center * subdural/GRID electrodes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epilepsy intractable are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Drug Resistant Epilepsy epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epilepsy intractable

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    19 sites in 12 countries. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • "Carol Davila" University of Medicine and Pharmacy

    Bucharest, Romania

  • Alfred Health

    Melbourne, Australia

  • Christian Doppler University Hospital Paracelsus Medical University Salzburg and Centre for Cognitive Neuroscience Salzburg

    Salzburg, 5020, Austria

  • Dalhousie Universiry and Hospital

    Dalhousie, Nova Scotia, Canada

  • Danish Epilepsy Centre, Aarhus Universitets Hospital

    Aarhus, 8200, Denmark

  • Department of Clinical Neurosciences chez CHUV; Centre Hospitalier Universitaire Vaudois

    Lausanne, Switzerland

  • Departmet of Neurology, Masaryk University Brno

    Brno, Czechia

  • Duke University Health System

    Durham, North Carolina, 27710, United States

  • Epilepsy Centre, University Hospital Freiburg

    Freiburg im Breisgau, Germany

  • Epilepsy Department University Hospitals of Marseille

    Marseille, France

  • Grenoble Institute of Neurosciences, Centre Hospitalier Universitaire Grenoble Alpes

    Grenoble, France

  • Hospital Universitario y Politecnico La Fe

    Valencia, Spain

  • Mater Health

    Brisbane, Australia

  • Monash University

    Melbourne, Victoria, 3800, Australia

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • Presbyterian-Shadyside Hospital

    Pittsburgh, Pennsylvania, 15232, United States

  • University School of Medicine Kyoto

    Kyoto, 606-8303, Japan

  • University of Florida College of Medicine

    Gainesville, Florida, 32610, United States

  • Wester University

    London, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.